Biora Therapeutics is a biotechnology company. Co. supports patients and physicians during patients' life decisions with its suite of molecular tests, including: Innatal Prenatal Screen, which is a noninvasive prenatal test provided to women early in pregnancy to screen for risk of fetal chromosomal conditions, such as Down syndrome and sex chromosome disorders; and Resura Prenatal Test for Monogenic Disease, which is a test for monogenic diseases. Co.'s precision medicine development pipeline includes Recoverable Sampling System, which is an ingestible capsule platform designed to enable the collection, preservation, and analysis of samples. We show 8 historical shares outstanding datapoints in our coverage of PROG's shares outstanding history.
Understanding the changing numbers of PROG shares outstanding — and
comprehending the concept of differing number of shares outstanding in general comparing companies like PROG versus peers —
is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies.
Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history.
With this page we aim to empower investors researching PROG by allowing them to research PROG shares outstanding history
as well as any other stock in our coverage universe. |
Free PROG Email Alerts:
Video: Shares Outstanding Importance
